Sign in: Staff/Students
Members of a patient-led consortium, whose clinical trials are led by the Royal Liverpool University Hospital, the University and 11 other partners, have won three awards for their ground-breaking work on rare disease.
DevelopAKUre were presented with the Rare Orphan Advocacy and Research (ROAR) awards at the World Orphan Drug Congress in Geneva, Switzerland.
DevelopAKUre is an international research collaboration, aiming to cure Black Bone Disease otherwise known as alkaptonuria or AKU.
The consortium received the Best European Industry-Patient Organisation Engagement award, Sobi, the speciality healthcare company which supplies the drugs, received Best Biotech Pipeline and PSR Orphan Experts, which provides logistical support at every stage of the trials, received Best Contract Research Organisation.
You must be logged in to post a comment.
All recent news
Lateral flow tests detect most people at risk of transmitting Covid-19
Free digital skills training for Liverpool students
Social disadvantage in the UK has a lasting impact on childhood asthma
Win a year’s tuition fees with Santander Universities UK
How to share your feedback with us – Student Feedback Hub
Professor Eithne Costello from @LivUni on the link between Type 2 Diabetes and Pancreatic Cancer #ITVTonight at 8pm.
Professor Chris Holloran of The University Of Liverpool (@LivUni) explains the importance of diagnosing Pancreatic Cancer early.
You can watch the full episode on #ITVTonight at 8pm
Researchers from @LivCancerRes feature in a new @ITVTonight film about #PancreaticCancer.
Profs Chris Halloran & Eithne Costello discuss the importance of early detection & the research taking place to help to improve outcomes.
📺 Watch 'Britain's Hidden Killer' on ITV at 8pm.